Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy

• Published in: Biomedicines 2023-04, Vol.11 (4), p.1105
• Main Authors: Congregado Ruiz, Belén, Rivero Belenchón, Inés, Lendínez Cano, Guillermo, Medina López, Rafael Antonio
• Format: Article
• Language: English
• Subjects: androgen receptor; Androgen receptors; Androgens; antiandrogen therapy; Antiandrogens; Antimitotic agents; Antineoplastic agents; Antisense oligonucleotides; Antisense therapy; Biosynthesis; bipolar antiandrogen therapy; Cancer; Cancer therapies; Care and treatment; Castration; castration-resistant prostate cancer; Cell cycle; Clomipramine; Drugs; Gene amplification; Health aspects; Indomethacin; Ligands; Metastasis; Metformin; Niclosamide; Patients; Prostate cancer; resensitizing to antiandrogens; Review; Testosterone; Tumor cells; Tumors
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines11041105

Since prostate cancer (PCa) was described as androgen-dependent, the androgen receptor (AR) has become the mainstay of its systemic treatment: androgen deprivation therapy (ADT). Although, through recent years, more potent drugs have been incorporated, this chronic AR signaling inhibition inevitably led the tumor to an incurable phase of castration resistance. However, in the castration-resistant status, PCa cells remain highly dependent on the AR signaling axis, and proof of it is that many men with castration-resistant prostate cancer (CRPC) still respond to newer-generation AR signaling inhibitors (ARSis). Nevertheless, this response is limited in time, and soon, the tumor develops adaptive mechanisms that make it again nonresponsive to these treatments. For this reason, researchers are focused on searching for new alternatives to control these nonresponsive tumors, such as: (1) drugs with a different mechanism of action, (2) combination therapies to boost synergies, and (3) agents or strategies to resensitize tumors to previously addressed targets. Taking advantage of the wide variety of mechanisms that promote persistent or reactivated AR signaling in CRPC, many drugs explore this last interesting behavior. In this article, we will review those strategies and drugs that are able to resensitize cancer cells to previously used treatments through the use of "hinge" treatments with the objective of obtaining an oncological benefit. Some examples are: bipolar androgen therapy (BAT) and drugs such as indomethacin, niclosamide, lapatinib, panobinostat, clomipramine, metformin, and antisense oligonucleotides. All of them have shown, in addition to an inhibitory effect on PCa, the rewarding ability to overcome acquired resistance to antiandrogenic agents in CRPC, resensitizing the tumor cells to previously used ARSis.